181 related articles for article (PubMed ID: 34224753)
1. Serological response to a single dose of a SARS-CoV-2 mRNA vaccine.
Ramos A; Cardoso MJ; Norton P; Sarmento A; Guimarães JT
J Virol Methods; 2021 Oct; 296():114223. PubMed ID: 34224753
[TBL] [Abstract][Full Text] [Related]
2. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
3. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
4. Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population.
Yin Q; Zhang Y; Lian L; Qu Y; Wu W; Chen Z; Pei R; Chen T; Sun L; Li C; Li A; Li J; Li D; Wang S; Guan W; Liang M
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452373
[TBL] [Abstract][Full Text] [Related]
5. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
[TBL] [Abstract][Full Text] [Related]
6. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.
Collier DA; Ferreira IATM; Kotagiri P; Datir RP; Lim EY; Touizer E; Meng B; Abdullahi A; ; Elmer A; Kingston N; Graves B; Le Gresley E; Caputo D; Bergamaschi L; Smith KGC; Bradley JR; Ceron-Gutierrez L; Cortes-Acevedo P; Barcenas-Morales G; Linterman MA; McCoy LE; Davis C; Thomson E; Lyons PA; McKinney E; Doffinger R; Wills M; Gupta RK
Nature; 2021 Aug; 596(7872):417-422. PubMed ID: 34192737
[TBL] [Abstract][Full Text] [Related]
7. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
8. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
[No Abstract] [Full Text] [Related]
13. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
14. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
[TBL] [Abstract][Full Text] [Related]
15. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
16. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
[TBL] [Abstract][Full Text] [Related]
17. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.
Saadat S; Rikhtegaran Tehrani Z; Logue J; Newman M; Frieman MB; Harris AD; Sajadi MM
JAMA; 2021 Apr; 325(14):1467-1469. PubMed ID: 33646292
[TBL] [Abstract][Full Text] [Related]
18. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.
Tauzin A; Nayrac M; Benlarbi M; Gong SY; Gasser R; Beaudoin-Bussières G; Brassard N; Laumaea A; Vézina D; Prévost J; Anand SP; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Niessl J; Tastet O; Gokool L; Morrisseau C; Arlotto P; Stamatatos L; McGuire AT; Larochelle C; Uchil P; Lu M; Mothes W; De Serres G; Moreira S; Roger M; Richard J; Martel-Laferrière V; Duerr R; Tremblay C; Kaufmann DE; Finzi A
Cell Host Microbe; 2021 Jul; 29(7):1137-1150.e6. PubMed ID: 34133950
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
20. Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine.
Komissarov AA; Dolzhikova IV; Efimov GA; Logunov DY; Mityaeva O; Molodtsov IA; Naigovzina NB; Peshkova IO; Shcheblyakov DV; Volchkov P; Gintsburg AL; Vasilieva E
J Immunol; 2022 Mar; 208(5):1139-1145. PubMed ID: 35101893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
